['bladder cancer']
['mitomycin c']

        Inclusion Criteria:

          -  Written informed consent

          -  NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or
             Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables

          -  Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis

          -  Aged 16 or over

          -  Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit
             of Normal (ULN)

          -  Negative pregnancy test for women of child-bearing potential

        Exclusion Criteria:

          -  Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant
             carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per
             year since initial diagnosis or in the past five years, whichever is shorter

          -  Any history of histologically confirmed non-TCC bladder cancer

          -  Trial entry recurrence identified within 11.5 months of the date of the original
             diagnosis

          -  Any prior treatment of the trial entry recurrence (including biopsy)

          -  Previous MMC chemotherapy other than a single instillation at diagnostic surgery

          -  Known allergy to MMC

          -  Carcinoma involving the prostatic urethra or upper urinary tract (participants should
             have had imaging of the upper urinary tract within 2 years prior to randomisation)

          -  Known or suspected reduced bladder capacity (<100ml)

          -  Significant bleeding disorder

          -  Female patients who are breast-feeding or are of childbearing potential and unwilling
             or unable to use adequate non-hormonal contraception. Male patients should also use
             contraception if sexually active.

          -  Active or intractable urinary tract infection

          -  Urethral stricture or anything impeding the insertion of a catheter

          -  Large narrow neck diverticula

          -  Significant urinary incontinence

          -  Any other conditions that in the Principal Investigator's opinion would contraindicate
             protocol treatment

          -  Unable or unwilling to comply with study procedures or follow up schedule
      